Shareholders in Portfolio Company
Investment Started: 2011
4.78 bln rubles
Co-investment by RUSNANO1.25 bln rubles
Full-cycle production of innovative nanomedicines via versatile GMP pharmaceutical manufacturer
NEARMEDIC will base its pharmaceutical production on Kagocel®, an antiviral drug available over the counter. Construction of the new GMP-tailored manufacturing facility will enable NEARMEDIC to remove Kagocel production from a rented facility and greatly expand manufacturing operations to further strengthen its Russian and the CIS market positions.
Kagocel is a compound of an active plant-based gossypol molecule with a nanosized polymer carrier. The joining of this small molecule to a highmolecular-weight polymer-carrier prevents rapid metabolism of the active ingredient in the organism, prolonging the drug’s pharmacological activity and avoiding toxicity. Therein lies its uniqueness. Kagocel elicits the formation of alpha- beta- and gamma-interferons in the human organism. The interferons have highly antiviral activity, effective in treatment and prevention of flu and other acute respiratory infections and in treatment of herpes infections.
Since entering the market, Kagocel’s sales have continued to rise at a faster pace that the rest of the antivirals in the Russian market. The drug is one of the top ten medicines sold in this segment.
Area of application
- Pharmaceutical distribution companies
- Highly effective
- Prolonged protection
- Universal antiviral mechanism
- Favorable safety profile
- Low allergenicity
- Lower cost of treatment
13 December 2013RUSNANO Exits Portfolio Company NEARMEDIC PHARMA
17 October 2011